News - Sanofi, Eli Lilly

Filter

Current filters:

SanofiEli Lilly

Popular Filters

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

13-05-2014

US pharma major Eli Lilly has released positive top-line results of three completed Phase III clinical…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

Sanofi sues Eli Lilly over Lantus patent infringement

Sanofi sues Eli Lilly over Lantus patent infringement

31-01-2014

French drug major Sanofi says it has filed a patent infringement suit against USA pharma firm Eli Lilly…

BiosimilarsDiabetesEli LillyLantusLegalNorth AmericaPatentsPharmaceuticalSanofiUSA

Global insulin market expanded to $20.8 billion in 2012

17-12-2013

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular…

Asia-PacificBayerChinaDiabetesEli LillyGlobalMarkets & MarketingNovo NordiskSanofi

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

10-12-2013

Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Geropharm to invest $45 million in Russian insulin production

Geropharm to invest $45 million in Russian insulin production

25-09-2013

Geropharm, one of Russia’s leading pharmaceutical and biotech companies, is establishing a plant for…

DiabetesEli LillyEuropeFinancialGeropharmNovo NordiskPharmaceuticalProductionSanofi

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Lilly and Boehringer Ingelheim's basal insulin MAA accepted by EMA

08-07-2013

US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July…

Boehringer IngelheimDiabetesEli LillyLantusNovo NordiskPharmaceuticalSanofiVictoza

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin

24-01-2013

Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada

02-11-2012

US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

Anti-clotting drugs prasugrel and clopidogrel yield similar results

27-08-2012

The TRILOGY ACS study, the first trial to study patients with acute coronary syndrome who do not undergo…

Bristol-Myers SquibbCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalPlavixResearchSanofi

More news from American Diabetes Association meeting

13-06-2012

Ongoing news from the American Diabetes Association meeting in Philadelphia (see also The Pharma Letter…

Boehringer IngelheimDiabetesEli LillyLantusLY2605541PharmaceuticalResearchSanofi

Highlights of American Diabetes Association meeting

11-06-2012

The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015

22-11-2011

The acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million…

Asia-PacificAstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalPlavixSanofi

Back to top